Selective androgen receptor modulators for treating diabetes
OwnerJames T. Dalton, Shontelle Dodson +1inventors
InventorsJames T. Dalton, Shontelle Dodson, Mitchell S. Steiner
Life of this patent
Estimating the term…
Abstract
This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC.
Claims28
A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of muscle wasting in a human subject with non-small cell lung cancer, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound of formula II:
- wherein
- X is O;
- Z is a hydrogen bond acceptor, NO2, CN, COR, CONHR;
- Y is a lipid soluble group, CF3, CH3, formyl, alkoxy, H, F, I, Br, Cl, Sn(R)3;
- R is an alkyl, aryl, phenyl, alkenyl, haloalkyl, haloalkenyl, halogen or OH;
- and
- Q is alkyl, halogen, N(R)2, CN, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR, acetamido-, trifluoroacetamido-, alkylamines, ether, alkyl, N-sulfonyl, O-sulfonyl, alkylsulfonyl, carbonyl, or a ketone.
A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of cachexia, pre-cachexia or early cachexia in a subject with non-small cell lung cancer, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound of formula II:
- wherein
- X is O;
- Z is a hydrogen bond acceptor, NO2, CN, COR, CONHR;
- Y is a lipid soluble group, CF3, CH3, formyl, alkoxy, H, F, I, Br, Cl, Sn(R)3;
- R is an alkyl, aryl, phenyl, alkenyl, haloalkyl, haloalkenyl, halogen or OH;
- and
- Q is alkyl, halogen, N(R)2, CN, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR, acetamido-, trifluoroacetamido-, alkylamines, ether, alkyl, N-sulfonyl, O-sulfonyl, alkylsulfonyl, carbonyl, or a ketone.
A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of pre-cachexia or early cachexia in a subject suffering from cancer, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound of formula II:
- wherein
- X is O;
- Z is a hydrogen bond acceptor, NO2, CN, COR, CONHR;
- Y is a lipid soluble group, CF3, CH3, formyl, alkoxy, H, F, I, Br, Cl, Sn(R)3;
- R is an alkyl, aryl, phenyl, alkenyl, haloalkyl, haloalkenyl, halogen or OH;
- and
- Q is alkyl, halogen, N(R)2, CN, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR, acetamido-, trifluoroacetamido-, alkylamines, ether, alkyl, N-sulfonyl, O-sulfonyl, alkylsulfonyl, carbonyl, or a ketone.
A method of treating, reducing the severity of, reducing the incidence of, delaying the onset of, loss of physical function in a subject suffering from cancer, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound of formula II:
- wherein
- X is O;
- Z is a hydrogen bond acceptor, NO2, CN, COR, CONHR;
- Y is a lipid soluble group, CF3, CH3, formyl, alkoxy, H, F, I, Br, Cl, Sn(R)3;
- R is an alkyl, aryl, phenyl, alkenyl, haloalkyl, haloalkenyl, halogen or OH;
- and
- Q is alkyl, halogen, N(R)2, CN, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR, acetamido-, trifluoroacetamido-, alkylamines, ether, alkyl, N-sulfonyl, O-sulfonyl, alkylsulfonyl, carbonyl, or a ketone.
A method of increasing the survival of a human subject with non-small cell lung cancer, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound of formula II:
- wherein
- X is O;
- Z is a hydrogen bond acceptor, NO2, CN, COR, CONHR;
- Y is a lipid soluble group, CF3, CH3, formyl, alkoxy, H, F, I, Br, Cl, Sn(R)3;
- R is an alkyl, aryl, phenyl, alkenyl, haloalkyl, haloalkenyl, halogen or OH;
- and
- Q is alkyl, halogen, N(R)2, CN, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSRNHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR, acetamido-, trifluoroacetamido-, alkylamines, ether, alkyl, N-sulfonyl, O-sulfonyl, alkylsulfonyl, carbonyl, or a ketone.
Dependencies are inferred from the claim text.